These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 3088461)

  • 41. Blood ammonia levels in epileptic children on 2 dose ranges of valproic acid monotherapy: a cross-sectional study.
    Sharma S; Gulati S; Kabra M; Kalra V; Vasisht S; Gupta YK
    J Child Neurol; 2011 Jan; 26(1):109-12. PubMed ID: 20921570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
    Cheng M; Tang X; Wen S; Yue J; Wang H
    Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nutritional influence on serum ammonia in young patients receiving sodium valproate.
    Laub MC
    Epilepsia; 1986; 27(1):55-9. PubMed ID: 3081337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
    Mehndiratta MM; Mehndiratta P; Phul P; Garg S
    J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum carnitine during valproic acid therapy.
    Laub MC; Paetzke-Brunner I; Jaeger G
    Epilepsia; 1986; 27(5):559-62. PubMed ID: 3093213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?
    Latour P; Biraben A; Polard E; Bentué-Ferrer D; Beauplet A; Tribut O; Allain H
    Hum Psychopharmacol; 2004 Apr; 19(3):193-203. PubMed ID: 15079854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
    Mojumder DK; De Oleo RR
    Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate.
    de Wolff FA; Peters AC; van Kempen GM
    Neuropediatrics; 1982 Feb; 13(1):10-3. PubMed ID: 6123089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
    Kwack DW; Kim DW
    Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Valproate-associated hyperammonemia and DL-carnitine supplement.
    Komatsu M; Kodama S; Yokoyama S; Konishi H; Tanaka K; Momota K; Wada H; Matsuo T
    Kobe J Med Sci; 1987 Jun; 33(3):81-7. PubMed ID: 2959815
    [No Abstract]   [Full Text] [Related]  

  • 51. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
    Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
    Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S; Mitsudome A; Yasumoto S; Ogawa A; Muta Y; Tomoda Y
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
    Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
    Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old].
    Motte J; Pedespan JM; Sevestre M; Chiron C;
    Arch Pediatr; 2005 Oct; 12(10):1533-9. PubMed ID: 16099147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
    Gidal BE; Inglese CM; Meyer JF; Pitterle ME; Antonopolous J; Rust RS
    Pediatr Neurol; 1997 May; 16(4):301-5. PubMed ID: 9258962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Sodium valproate: a hyperammonemic drug. Study in the epileptic and healthy volunteer].
    Marescaux C; Warter JM; Laroye M; Rumbach L; Micheletti G; Koehl C; Imler M; Kurtz D
    J Neurol Sci; 1983 Feb; 58(2):195-209. PubMed ID: 6403673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of valproate therapy on thrombin generation determined by calibrated automated thrombography.
    Topf HG; Lischetzki G; Trollmann R; Rascher W; Rauh M
    Klin Padiatr; 2011 May; 223(3):165-8. PubMed ID: 21472635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
    Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
    Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-carnitine replacement therapy in chronic valproate treatment.
    Melegh B; Kerner J; Acsádi G; Lakatos J; Sándor A
    Neuropediatrics; 1990 Feb; 21(1):40-3. PubMed ID: 2107456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.